EVE Health Group (ASX:EVE) completed the acquisition of Nextract after the deal was settled through the issue of 83.3 million fully paid ordinary shares in the firm at a post-consolidation price of AU$0.036 per share, according to a Thursday Australian bourse filing.

It also completed a AU$1 million placement to sophisticated and professional investors, issuing 27.8 million shares at the same price, with the proceeds to fund the integration, initial manufacturing scale-up, and regulatory submissions for Nextract.

It also opened its share purchase plan for existing shareholders to raise up to AU$500,000.

Further, the company appointed Stuart Gunzburg as its Chief Scientific Officer.